EquityBulls

Latest News

Keywords Selected: Wockhardt

Stock Report

Wockhardt Ltd Q4 FY2025-26 consolidated PAT jumps to Rs. 166 crores
Wockhardt files Marketing Authorisation Application for WCK 5222 with European Medicines Agency
European Medicines Agency Grants Accelerated Assessment to WCK 5222
US FDA Accepts Wockhardt's New Drug Application for Breakthrough Antibiotic Zaynich
Wockhardt Ltd reports consolidated PAT of Rs. 78 crores in Q2 FY2026
Wockhardt Submits New Drug Application to U.S. FDA for Zidebactam-Cefepime for Treatment of Serious GramNegative Infections
THE LANCET Regional Health publishes Pivotal Phase 3 Clinical Study on Miqnaf®
Shukra Pharmaceuticals Ltd inks Strategic PAN India Distribution tie-up with Wockhardt Limited
Leading U.K. Medical Journal publishes a Complex Case of Severe Pandrug Resistant Infection in U.S. Liver Transplant Patient Successfully Treated with Zaynich®
Wockhardt initiates strategic realignment of US Operations to focus on Innovative Portfolio
Senores Pharmaceuticals acquires ANDA for Topiramate HCl 25, 50, 100 and 200 mg tablets
Paediatric US Cancer Patient with Recalcitrant Blood and Liver Infection Successfully Treated with Zaynich™
Zaynich™ enables US cancer patient undergo successful liver transplant and resume chemotherapy by eradicating dual extreme drug resistant Gram negative pathogens
Wockhardt files fast-acting Insulin Aspart injection with DCGI
Wockhardt's yet another novel antibiotic Miqnaf™ receives favourable recommendation from Subject Expert Committee of CDSCO for the Treatment of CABP
Dr. Habil Khorakiwala bestowed Lifetime Achievement Award by Integrated Health and Wellbeing Council in Dubai
Wockhardt's Investigational Drug, Zaynich™ cures complex case of meningitis caused by pan-drug resistant super-bug under compassionate use
Wockhardt wins prestigious Innovator Award from Government of India
Globally renowned US body CLSI awards high susceptibility breakpoints to Zaynich
Wockhardt announces successful completion of pivotal Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873
Wockhardt Ltd reports consolidated loss of Rs. 77 crores in Q2 FY2024
Wockhardt Ltd Q1FY24 consolidated loss at Rs. 134 crores
Wockhardt Ltd Q4 FY2023 consolidated loss at Rs. 208 crores
Wockhardt Ltd Q3 FY2023 consolidated loss at Rs. 96 crores